Novavax (NVAX)
(Delayed Data from NSDQ)
$18.17 USD
-1.39 (-7.08%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $18.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Novavax, Inc. [NVAX]
Reports for Purchase
Showing records 141 - 160 ( 296 total )
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for NVAX.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for NVAX.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Final Analysis Confirms NVX-CoV2373?s High Level of Efficacy; Raising PT to $317
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
After Traveling at Warp Speed, NVX-CoV2373 Has Now Arrived; Reiterate Buy and $207 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Update Confirms COVID-19 Vaccine Phase 3 Start Is on Track for December; Reiterate Buy and $207 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
While the COVID-19 Pandemic Waits for No One, Some Are Worth the Wait
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Critical International Recognition of NVX-CoV2373 Grows; Reiterate Buy and $290 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V